Agomab Employee Directory
Biotechnology ResearchFlanders, Belgium51-200 Employees
Agomab is a mid-sized biotechnology company based in Antwerp, Belgium, focused on fibro-inflammatory diseases. It leverages deep expertise in growth factor biology to develop therapies that aim to resolve fibrosis, repair tissue structure, and restore organ function. The company is pursuing a broad clinical pipeline of differentiated, disease-modifying programs targeting severe organ failure and fibrotic diseases, anchored in new scientific insights and a long-term development strategy. Its work targets patients with fibrotic conditions, including Crohn's disease–related fibrosis and idiopathic pulmonary fibrosis, seeking to address the underlying disease processes. In June 2026, Agomab announced the design of its NOV-ERA Phase 2b study for ontunisertib in Fibrostenosing Crohn's Disease, noting FDA alignment and first participant dosing anticipated in the second half of 2026.
1-888-653-2347 
support@leadiq.com 
